Menu

Quality and GMP Compliance for Virtual Companies (Pharmaceutical and Biologics Industries)

By Visited 1 times , 1 Visits today

Start Date: 2021-03-29
End Date: 2021-03-30
Time: 11:00 am to 5:00 pm

Phone: +1-888-717-2436

Location: virtul Seminar,6201 America Center Drive Suite 240 San Jose, CA 95002, USA

Website

Get Direction View Large Map

Description

Day 01(11:00 AM – 5:00 PM EDT)

11.00 AM: Session Start
Introductions and participant expectations for the program
Fundamentals of Good Manufacturing Practice
What is GMP?
Purpose of GMP
Basis in law: US, Europe, Canada
Elements that apply to all virtual companies
Elements that depend on how operations are conducted: How to tell what applies to your company
Data Integrity: What it is and why it is important to GMP
Fundamentals of Good Clinical Practice (GCP)
What is GCP?
Purpose of GCP
Basis in law: US, Europe, Canada
Elements that apply to all virtual companies
Elements that depend on how operations are conducted: How to tell what applies to your company
Regulatory and business risks: The case for compliance
Virtual company organizational structure and responsibility for QA/GMP/GCP
Virtual company quality system structure and management
Policies, procedures, documentation management
Metrics and management review considerations
Selection, qualification and monitoring of contractors
Initial due diligence – public information sources to gage compliance
Qualification of vendors
Quality agreements – determining and documenting responsibilities for GMP
Vendor audit program
Day One Q&A and recap of progress meeting stated course expectations

Day 02(11:30 AM – 5:30 PM EDT)

Regulatory Inspections
Purpose of an inspection
Reasons for inspections
Inspections at virtual company headquarters locations – purpose and scope
Inspections at CMOs and Contract Labs
GMP inspections versus Preapproval inspections – FDA
GCP inspections of sponsors of clinical trials
EMA inspections – contrast with FDA
Health Canada inspections
Logistics for managing inspections at your location
Information sources about inspections on agency web sites: What you need and how to find it easily
Preparation for inspections
Overall process – ready room support
Receiving and hosting the inspectors
Providing documents
Answering questions
Interpersonal dos and don’ts for interacting with inspectors
Managing the exit discussion at the conclusion of the inspection
Inspections at your contract organizations
Making sure your CMO and contract lab are “PAI ready”
Training employees to assure inspection readiness – pitfalls to make sure you avoid
Conducting mock inspections effectively
Post-inspection communications with the inspecting agency
How to write an effective response
Common mistakes to avoid
Following up to ensure the response is satisfactory
When to request a meeting, and if granted, how best to handle it
Enforcement considerations
FDA enforcement process – domestic and ex-US
EMA enforcement
Health Canada
Final Q&A, discussion, and conclusion
4:30 PM: Adjourn

Registration Information

Click the link for registration or ticketing information:

Registration URL

Organizers

Organized by :  Complianceonline

About the Organizers :

Today, many companies operate on an outsourcing model. This is very common for companies who are evolving from being mainly development-focused to a point where they are entering latter stages of Phase 2 or Phase 3 clinical trials, and plan to have a product ready for market approval in the coming months. Most such companies are small, and may not have deep expertise in QA and GMP compliance, relying on their partners to cover those areas. Companies who outsource the majority of operations through the use of Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs) and Contract Laboratories, however, remain responsible for the quality and compliance status of the products they send to the clinic or to the marketplace.